TY - JOUR

T1 - Novel Insights in the Management of Vernal Keratoconjunctivitis (VKC)

T2 - European Expert Consensus Using a Modified Nominal Group Technique

AU - Dahlmann-Noor, Annegret

AU - Bonini, Stefano

AU - Bremond-Gignac, Dominique

AU - Heegaard, Steffen

AU - Leonardi, Andrea

AU - Montero, Jesús

AU - Silva, Eduardo D.

AU - The EUR-VKC Group

N1 - Publisher Copyright: © 2023, The Author(s).

PY - 2023

Y1 - 2023

N2 - Introduction: Vernal keratoconjunctivitis (VKC) is a rare, severe allergic ocular disease, typically occurring in children and adolescents, that can have a significant impact on quality of life and lead to visual impairment. Long-term treatment may be necessary to tackle chronic inflammation and topical corticosteroid dependency must be minimised due to the risk of complications. There is a need for unified clinical guidance to aid the assessment, diagnosis and management of VKC across Europe. The aim of this expert panel (the EUR-VKC Group) was to provide clear guidance for primary care physicians and general ophthalmologists involved in the diagnosis and management of VKC. Methods: An expert group of seven European ophthalmologists was convened and a modified nominal group technique used to develop key recommendations on VKC management. The recommendations were subject to up to two rounds of voting using a 5-point Likert scale to ascertain consensus and the strength of each recommendation. Consensus was set at a predetermined threshold of ≥ 75.0% of experts selecting ‘Strongly agree’ or ‘Agree’. Results: A total of 47 recommendations were developed relating to the assessment of key of VKC, guidance on who and when to refer, as well as treatment-escalation pathways, long-term follow-up, and supportive care and education. All recommendations reached consensus after two rounds. The group emphasise how timely diagnosis and treatment initiation that is appropriate to disease severity are crucial to benefit patients with VKC. Patients with signs (‘red flags’) indicating severe VKC, or persistent mild-to-moderate VKC that is non-responsive following 2–4 weeks of treatment, should be referred to a sub-specialist. Conclusion: The EUR-VKC Group provides recommendations on the assessment, diagnosis, management, referral and follow-up of patients with VKC. It also provides a framework to facilitate collaboration between primary care physicians, general ophthalmologists and sub-specialists to improve the outcomes for patients with VKC.

AB - Introduction: Vernal keratoconjunctivitis (VKC) is a rare, severe allergic ocular disease, typically occurring in children and adolescents, that can have a significant impact on quality of life and lead to visual impairment. Long-term treatment may be necessary to tackle chronic inflammation and topical corticosteroid dependency must be minimised due to the risk of complications. There is a need for unified clinical guidance to aid the assessment, diagnosis and management of VKC across Europe. The aim of this expert panel (the EUR-VKC Group) was to provide clear guidance for primary care physicians and general ophthalmologists involved in the diagnosis and management of VKC. Methods: An expert group of seven European ophthalmologists was convened and a modified nominal group technique used to develop key recommendations on VKC management. The recommendations were subject to up to two rounds of voting using a 5-point Likert scale to ascertain consensus and the strength of each recommendation. Consensus was set at a predetermined threshold of ≥ 75.0% of experts selecting ‘Strongly agree’ or ‘Agree’. Results: A total of 47 recommendations were developed relating to the assessment of key of VKC, guidance on who and when to refer, as well as treatment-escalation pathways, long-term follow-up, and supportive care and education. All recommendations reached consensus after two rounds. The group emphasise how timely diagnosis and treatment initiation that is appropriate to disease severity are crucial to benefit patients with VKC. Patients with signs (‘red flags’) indicating severe VKC, or persistent mild-to-moderate VKC that is non-responsive following 2–4 weeks of treatment, should be referred to a sub-specialist. Conclusion: The EUR-VKC Group provides recommendations on the assessment, diagnosis, management, referral and follow-up of patients with VKC. It also provides a framework to facilitate collaboration between primary care physicians, general ophthalmologists and sub-specialists to improve the outcomes for patients with VKC.

KW - Consensus

KW - Europe

KW - Expert panel method

KW - Management

KW - Vernal keratoconjunctivitis

KW - VKC

U2 - 10.1007/s40123-023-00665-5

DO - 10.1007/s40123-023-00665-5

M3 - Journal article

C2 - 36790673

AN - SCOPUS:85148358605

VL - 12

SP - 1207

EP - 1222

JO - Ophthalmology and Therapy

JF - Ophthalmology and Therapy

SN - 2193-8245

ER -